Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312845 · ClinicalTrials.gov registry record · Phase 3
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 3 study of Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
- 20
- Study locations
NCT00312845 is a Phase 3 study of Non-Hodgkin's Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 676 participants, above the 211-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (220% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00312845, a Phase 3 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bortezomib + Rituximab
Study Locations (20)
California
- Central Hematology Oncology Medical Group, Inc - Alhambra
- Comprehensive Blood and Cancer Center - Bakersfield
- Providence Saint Joseph Medical Center - Burbank
- St. Jude Heritage Medical Group - Fullerton
- Wilshire Oncology Medical Group, Inc. - La Verne
- Pacific Shores Medical Group - Long Beach
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- North Valley Hematology Oncology - Mission Hills
- University of California, Irvine Medical Center - Orange
- Ventura County Hematology-Oncology Specialists - Oxnard
- Cancer Care Associates Medical Group, Inc. - Redondo Beach
- Central Coast Medical Oncology Corporation - Santa Maria
Florida
- Integrated Community Oncology Network - Jacksonville
- Innovative Clinical Research of South Florida - Miami
- Palm Beach Cancer Institute - West Palm Beach
Connecticut
- Norwalk Medical Group - Norwalk
- Hematology Oncology PC - Stamford
Alabama
- East Alabama Medical Center - Opelika
Georgia
- Emory Univeersity ,Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312845
The ClinicalTrials.gov registry entry for NCT00312845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 211-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (220% higher). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00312845 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00312845 about?
NCT00312845 is a clinical study titled "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma". The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituxima...
What is the current status of trial NCT00312845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2006-03. Estimated completion is 2010-07.
What conditions does trial NCT00312845 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00312845?
The interventions under investigation include: Rituximab (DRUG), Bortezomib + Rituximab (DRUG).
Who is sponsoring clinical trial NCT00312845?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312845 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
COMPLETED · Phase 3
-
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
COMPLETED · Phase 3
-
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
COMPLETED · Phase 3
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.